Phathom Pharmaceuticals, Inc. (PHAT): Shareholders' Equity
-$438.17M
As of 2025-12-31
-$344.27M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$438.17M | n/m | 2026-02-26, Balance as of period end |
| 2024-12-31 | -$253.58M | n/m | 2026-02-26, Balance as of period end |
| 2023-12-31 | -$72.76M | n/m | 2025-03-06, Balance as of period end |
| 2022-12-31 | -$74.81M | n/m | 2024-06-14, Balance as of period end |
| 2021-12-31 | $72.16M | -62.9% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $194.27M | -14.8% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $227.96M | n/m | 2021-03-30, Balance as of period end |
| 2018-12-31 | -$1.29M | n/a | 2020-03-19, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | -$438.17M | n/m |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $502.64M | +25.1% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $64.63M | -77.6% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $33.59M | -3.0% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $352.46M | +53.9% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $212.38M | -34.7% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $139.07M | +540.0% |
| Liquidia Corp (LQDA) | 2025-12-31 | $44.75M | -43.6% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $14.33M | n/m |
Compare PHAT, CYRX, SNDX, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗